ArticleJournal of the American Heart Association2022
Prognostic Cardiac Magnetic Resonance Markers of Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy for Predicting Heart Failure Outcomes.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Cardiac Magnetic Resonance Imaging and Arrhythmic Risk Stratification in Cardiomyopathies.Journal of clinical medicine · 2025Review
- Cardiac Magnetic Resonance in Heart Failure: Diagnostic and Prognostic Assessments.Journal of cardiovascular development and disease · 2025Review
- Risk stratification in arrhythmogenic cardiomyopathy: scoring or personalized medicine?European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Prognostic value of right ventricular trabecular complexity in patients with arrhythmogenic cardiomyopathy.European radiology · 2024Article
- Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research.Biomedicines · 2024Review
- LV-predominant arrhythmogenic cardiomyopathy related to pathogenic DSP-variant.Clinical case reports · 2024Article
- Multiparametric Mapping via Cardiovascular Magnetic Resonance in the Risk Stratification of Ventricular Arrhythmias and Sudden Cardiac Death.Medicina (Kaunas, Lithuania) · 2024Review
- Imaging Features of Arrhythmogenic Cardiomyopathies.Radiographics : a review publication of the Radiological Society of North America, Inc · 2024Article
- Arrhythmogenic Cardiomyopathy: Definition, Classification and Arrhythmic Risk Stratification.Journal of clinical medicine · 2024Review
- Cardiac MRI and Clinical Outcomes inRadiology. Cardiothoracic imaging · 2023Article
- Utilities and Limitations of Cardiac Magnetic Resonance Imaging in Dilated Cardiomyopathy.Korean journal of radiology · 2023Review
- Value of cardiac magnetic resonance on the risk stratification of cardiomyopathies.World journal of cardiology · 2023Review
- Dilated Cardiomyopathy: A Comprehensive Approach to Diagnosis and Risk Stratification.Biomedicines · 2023Review
- Cardiac magnetic resonance imaging of arrhythmogenic cardiomyopathy: evolving diagnostic perspectives.European radiology · 2023Review
- The Many Faces of Arrhythmogenic Cardiomyopathy: An Overview.The application of clinical genetics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Left ventricular (LV) involvement is frequently observed in arrhythmogenic cardiomyopathy (ACM). We investigated the association of LV myocardial assessment using cardiac magnetic resonance (CMR) with clinical outcomes including heart failure (HF)-related events in ACM. Methods and Results We retrospectively analyzed 60 patients with ACM between 2005 and 2020 according to the 2010 Task Force Criteria and assessed HF-related events (HF hospitalization, heart transplantation, and cardiac death) and ventricular tachycardia events. We analyzed CMR findings including late gadolinium enhancement (LGE) in all subjects and obtained mapping values (native T1, extracellular volume, and T2) on 30 (50%) patients out of them. Among the study population (mean age 49 years, 77% male), 41 (68%) patients had LV LGE. During a median follow-up of 34 months, there were 13 (22%) HF-related events, and 20 (30%) ventricular tachycardia events. Kaplan-Meier survival analysis revealed that HF-related events occurred only in patients with LV LGE (+) (versus LV LGE (-), log-rank
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.